Impact of Metabolic Syndrome on the Mortality Rate among Participants in a Specific Health Check and Guidance Program in Japan.
all-cause mortality rate
cardiovascular disease (CVD)
metabolic syndrome
obesity
social burden
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
pubmed:
17
7
2020
medline:
23
3
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
Objective In Japan, the Specific Health Check and Guidance (Tokutei-Kenshin) program was started in 2008 to decrease the social burden related to metabolic syndrome (MetS). However, so far this program has not been found to have any impact on the mortality rate. Methods The subjects consisted of individuals who participated in the Tokutei-Kenshin in seven districts between 2008 and 2015. Using a National database of death certificates, we identified those who might have died and then further confirmed such deaths with the collaboration of the regional National Health Insurance agency and public health nurses. The diagnosis of MetS was made according to the Japanese criteria. The causes of death were classified by ICD-10. Mortality risk was evaluated after adjusting for age, sex, smoking, alcohol intake and past medical history such as stroke, heart disease and kidney disease. Results Among the total of 664,926 subjects, we identified 8,051 fatal cases by the end of 2015. The crude death rate was 1.6% for those with MetS, 1.3% for those with preliminary metabolic syndrome, and 1.1% those without MetS. In MetS, the adjusted hazard ratio (95% confidence interval) was 1.08 (1.02-1.15) for all-cause and 1.39 (1.22-1.58) for cardiovascular disease mortality when the reference was for those without MetS. Conclusion The death rate was found to be significantly higher among the participants with MetS.
Identifiants
pubmed: 32669499
doi: 10.2169/internalmedicine.4975-20
pmc: PMC7691040
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2671-2678Références
Clin Exp Nephrol. 2014 Dec;18(6):885-91
pubmed: 24515308
Nephrology (Carlton). 2011 Sep;16(7):633-41
pubmed: 21771177
Clin Exp Nephrol. 2018 Aug;22(4):850-859
pubmed: 29330695
Clin Exp Nephrol. 2018 Apr;22(2):388-394
pubmed: 28815319
Hypertension. 2015 Jul;66(1):30-6
pubmed: 25987664
Kidney Int. 2008 Feb;73(4):391-8
pubmed: 18094682
Am J Hypertens. 2012 Mar;25(3):342-7
pubmed: 22089103
Kidney Int. 2003 Mar;63(3):793-808
pubmed: 12631061
Clin Exp Nephrol. 2017 Dec;21(6):978-985
pubmed: 28258498
Circ J. 2009 May;73(5):878-84
pubmed: 19282609
Diabetes Care. 2012 Jun;35(6):1310-5
pubmed: 22474041
Diabetol Metab Syndr. 2019 Jan 9;11:3
pubmed: 30636976
Intern Med. 2017;56(12):1475-1484
pubmed: 28626171
Diabetes Care. 2005 Jul;28(7):1769-78
pubmed: 15983333
Kidney Int. 2004 May;65(5):1870-6
pubmed: 15086929
Am J Kidney Dis. 2015 Dec;66(6):972-83
pubmed: 26145254
Clin Exp Nephrol. 2018 Dec;22(6):1331-1340
pubmed: 29869754
J Nephrol. 2008 May-Jun;21(3):305-12
pubmed: 18587718
Nephrol Dial Transplant. 2018 May 1;33(5):825-832
pubmed: 28992249
Kidney Int. 2016 Sep;90(3):665-73
pubmed: 27344204
Kidney Int. 2006 Jan;69(2):369-74
pubmed: 16408128
Int Heart J. 2008 Mar;49(2):193-203
pubmed: 18475019
N Engl J Med. 2016 Sep 1;375(9):905-6
pubmed: 27579659
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Clin Exp Nephrol. 2012 Apr;16(2):244-9
pubmed: 22057582
Clin Exp Nephrol. 2018 Apr;22(2):346-352
pubmed: 28744566
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169